JP2015524473A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524473A5 JP2015524473A5 JP2015526643A JP2015526643A JP2015524473A5 JP 2015524473 A5 JP2015524473 A5 JP 2015524473A5 JP 2015526643 A JP2015526643 A JP 2015526643A JP 2015526643 A JP2015526643 A JP 2015526643A JP 2015524473 A5 JP2015524473 A5 JP 2015524473A5
- Authority
- JP
- Japan
- Prior art keywords
- eye
- corneal
- hydrogel matrix
- item
- reservoir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 27
- 229940124597 therapeutic agent Drugs 0.000 claims description 17
- 239000000017 hydrogel Substances 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 239000000560 biocompatible material Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 210000005036 nerve Anatomy 0.000 claims description 9
- 230000008929 regeneration Effects 0.000 claims description 9
- 238000011069 regeneration method Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 208000028006 Corneal injury Diseases 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- -1 binaxaton Chemical compound 0.000 claims description 6
- 201000000159 corneal neovascularization Diseases 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 206010011777 Cystinosis Diseases 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical compound CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940088710 antibiotic agent Drugs 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- 229960001334 corticosteroids Drugs 0.000 claims description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 4
- 206010023332 keratitis Diseases 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 108020004999 messenger RNA Proteins 0.000 claims description 4
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 claims description 4
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- 229940126586 small molecule drug Drugs 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- 229960004402 tiopronin Drugs 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 206010055665 Corneal neovascularisation Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 3
- 208000001860 Eye Infections Diseases 0.000 claims description 3
- 208000020564 Eye injury Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 3
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 210000004087 cornea Anatomy 0.000 claims description 3
- 201000007717 corneal ulcer Diseases 0.000 claims description 3
- 208000011323 eye infectious disease Diseases 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000029663 wound healing Effects 0.000 claims description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 206010015911 Eye burns Diseases 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 229920002807 Thiomer Polymers 0.000 claims description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 2
- 229960004150 aciclovir Drugs 0.000 claims description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 2
- 229940120638 avastin Drugs 0.000 claims description 2
- 229960004099 azithromycin Drugs 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229960003405 ciprofloxacin Drugs 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 210000000795 conjunctiva Anatomy 0.000 claims description 2
- 208000021921 corneal disease Diseases 0.000 claims description 2
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960003722 doxycycline Drugs 0.000 claims description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims description 2
- 238000000609 electron-beam lithography Methods 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- IBYCYJFUEJQSMK-UHFFFAOYSA-N etifoxine Chemical compound O1C(NCC)=NC2=CC=C(Cl)C=C2C1(C)C1=CC=CC=C1 IBYCYJFUEJQSMK-UHFFFAOYSA-N 0.000 claims description 2
- 229960003817 etifoxine Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960003151 mercaptamine Drugs 0.000 claims description 2
- 238000001020 plasma etching Methods 0.000 claims description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 2
- 229920006295 polythiol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- MICLTPPSCUXHJT-UHFFFAOYSA-M potassium;4-[3-(6-oxo-3h-purin-9-yl)propanoylamino]benzoate Chemical compound [K+].C1=CC(C(=O)[O-])=CC=C1NC(=O)CCN1C(NC=NC2=O)=C2N=C1 MICLTPPSCUXHJT-UHFFFAOYSA-M 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 229960003787 sorafenib Drugs 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 229960004394 topiramate Drugs 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims 1
- 238000005459 micromachining Methods 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679908P | 2012-08-06 | 2012-08-06 | |
| US61/679,908 | 2012-08-06 | ||
| US201361775891P | 2013-03-11 | 2013-03-11 | |
| US61/775,891 | 2013-03-11 | ||
| PCT/US2013/053805 WO2014025792A1 (en) | 2012-08-06 | 2013-08-06 | Therapeutics dispensing device and methods of making same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524473A JP2015524473A (ja) | 2015-08-24 |
| JP2015524473A5 true JP2015524473A5 (enExample) | 2016-08-18 |
| JP6275137B2 JP6275137B2 (ja) | 2018-02-07 |
Family
ID=50068523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015526643A Expired - Fee Related JP6275137B2 (ja) | 2012-08-06 | 2013-08-06 | 治療薬分与デバイスおよびその作製方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10251778B2 (enExample) |
| EP (1) | EP2879761A4 (enExample) |
| JP (1) | JP6275137B2 (enExample) |
| AU (1) | AU2013299785B2 (enExample) |
| CA (1) | CA2881010A1 (enExample) |
| WO (1) | WO2014025792A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5505760B2 (ja) | 2005-09-27 | 2014-05-28 | ティッシュテク・インコーポレーテッド | 羊膜調製物及び精製組成物及びその使用方法 |
| EP2968113B8 (en) * | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| CN107430118A (zh) * | 2013-06-27 | 2017-12-01 | 广东盛泽康华生物医药有限公司 | 对自身免疫状况的分类与管理的方法与仪器 |
| US10613356B2 (en) * | 2013-09-09 | 2020-04-07 | The General Hospital Corporation | Remotely controllable lens device |
| FR3016881B1 (fr) * | 2014-01-29 | 2016-03-04 | Biocodex | Traitement des degenerescences et des lesions photo-induites de la retine |
| CN110236239B (zh) | 2014-02-10 | 2022-03-29 | 菲利普莫里斯生产公司 | 具有流体可渗透加热器组件的气溶胶生成系统 |
| KR20170040798A (ko) | 2014-08-08 | 2017-04-13 | 포사이트 비젼4, 인크. | 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법 |
| US12667548B2 (en) | 2014-11-07 | 2026-06-30 | Nacuity Pharmaceuticals, Inc. | Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide |
| US20160243288A1 (en) * | 2015-02-23 | 2016-08-25 | Tissuetech, Inc. | Apparatuses and methods for treating ophthalmic diseases and disorders |
| US12551509B2 (en) | 2015-11-18 | 2026-02-17 | Lucina Patent Holdco, Llc | Acellular regenerative products and methods of their manufacture |
| MX2019004562A (es) | 2016-10-19 | 2019-08-05 | Swimc Llc | Polimeros acrilicos y composiciones que contienen tales polimeros. |
| CA3057569A1 (en) * | 2017-03-29 | 2018-10-04 | Azura Ophthalmics Ltd. | Agents for increasing meibomian gland lipid secretion |
| US20200253867A1 (en) | 2017-09-22 | 2020-08-13 | University Of Florida Research Foundation | Devices and methods for reducing cystine crystals in vivo |
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| WO2020146362A1 (en) * | 2019-01-09 | 2020-07-16 | Verily Life Sciences Llc | Eye mounted device for therapeutic agent release |
| WO2020146660A1 (en) | 2019-01-11 | 2020-07-16 | Nacuity Pharmaceuticals, Inc. | N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis |
| WO2020150226A1 (en) * | 2019-01-15 | 2020-07-23 | University Of Utah Research Foundation | Drug-delivering nerve wrap |
| CA3143071A1 (en) | 2019-07-26 | 2021-02-04 | Proqr Therapeutics Ii B.V. | Ophthalmic compositions comprising viscosifying polymers and nucleic acids |
| EP4087655A4 (en) | 2020-01-10 | 2024-02-21 | Azura Ophthalmics Ltd | INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY |
| US20210378993A1 (en) * | 2020-06-08 | 2021-12-09 | Nacuity Pharmaceuticals, Inc. | Treatment of cystinosis |
| EP3922282A1 (en) * | 2020-06-09 | 2021-12-15 | Dompe' Farmaceutici S.P.A. | New drug delivery system for ophtalmic use |
| US12589072B2 (en) | 2020-11-11 | 2026-03-31 | Hadasit Medical Research Services And Development Ltd. | Bioadhesive film and methods of use thereof |
| WO2022204374A1 (en) * | 2021-03-24 | 2022-09-29 | Ocular Therapeutix, Inc. | Implant injector device |
| IT202200008621A1 (it) * | 2022-04-29 | 2023-10-29 | Sifi Spa | Composizione farmaceutica in microemulsione per il trattamento dei disturbi del segmento anteriore dell'occhio |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5788957A (en) * | 1991-10-15 | 1998-08-04 | Advanced Corneal Systems, Inc. | Enzyme-orthokeratology |
| US7070590B1 (en) * | 1996-07-02 | 2006-07-04 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| DE60025539T2 (de) * | 1999-11-01 | 2006-07-27 | Praful Poway Doshi | Getönte kontaktlinse aus kunststoff und verfahren zu deren herstellung |
| DE60219607T2 (de) | 2001-01-09 | 2007-12-27 | Microchips, Inc., Bedford | Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation |
| WO2006039558A2 (en) | 2004-10-09 | 2006-04-13 | Formurex, Inc. | Ocular agent delivery systems |
| US20070141106A1 (en) * | 2005-10-19 | 2007-06-21 | Bonutti Peter M | Drug eluting implant |
| US7878650B2 (en) * | 2006-06-29 | 2011-02-01 | Fritsch Michael H | Contact lens materials, designs, substances, and methods |
| AU2007338210B2 (en) * | 2006-12-22 | 2013-01-31 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| US9125807B2 (en) * | 2007-07-09 | 2015-09-08 | Incept Llc | Adhesive hydrogels for ophthalmic drug delivery |
| WO2009042231A2 (en) * | 2007-09-27 | 2009-04-02 | Akina, Inc. | Sol-gel phase-reversible hydrogel templates and uses thereof |
| EP2962682B1 (en) * | 2008-12-11 | 2018-03-28 | Massachusetts Institute Of Technology | Method of making a contact lens drug delivery device |
| US20120014970A1 (en) * | 2009-01-09 | 2012-01-19 | Reza Dana | Therapeutic Compositions for Treatment of Corneal Disorders |
| JP5890182B2 (ja) * | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | ヒドロゲルプラグによる薬物送達 |
| EP2427179A4 (en) * | 2009-05-04 | 2013-09-11 | Psivida Inc | POROUS PARTICLES FOR THE RELEASE OF SILICIUM MEDICINES |
| US9005649B2 (en) * | 2009-07-14 | 2015-04-14 | Board Of Regents, The University Of Texas System | Methods for making controlled delivery devices having zero order kinetics |
| AU2011285637B2 (en) | 2010-08-05 | 2014-10-30 | Forsight Vision4, Inc. | Subconjunctival implant for posterior segment drug delivery |
-
2013
- 2013-08-06 CA CA2881010A patent/CA2881010A1/en not_active Abandoned
- 2013-08-06 JP JP2015526643A patent/JP6275137B2/ja not_active Expired - Fee Related
- 2013-08-06 WO PCT/US2013/053805 patent/WO2014025792A1/en not_active Ceased
- 2013-08-06 AU AU2013299785A patent/AU2013299785B2/en not_active Ceased
- 2013-08-06 EP EP13828037.5A patent/EP2879761A4/en not_active Withdrawn
- 2013-08-06 US US14/420,295 patent/US10251778B2/en not_active Expired - Fee Related
-
2019
- 2019-03-05 US US16/293,220 patent/US20190282398A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Subrizi et al. | Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties | |
| Allyn et al. | Considerations for polymers used in ocular drug delivery | |
| Morrison et al. | Advances in ophthalmic drug delivery | |
| Thrimawithana et al. | Drug delivery to the posterior segment of the eye | |
| Joseph et al. | Drug delivery to the eye: what benefits do nanocarriers offer? | |
| JP7026507B2 (ja) | 眼において薬物徐放を達成する方法及び生体適合性組成物 | |
| Kompella et al. | Recent advances in ophthalmic drug delivery | |
| US10583221B2 (en) | Method of corneal transplantation or corneal inlay implantation with cross-linking | |
| Barar et al. | Advanced drug delivery and targeting technologies for the ocular diseases | |
| CN101052435B (zh) | 治疗介质递送装置 | |
| Yavuz et al. | Ocular drug delivery | |
| CN105792812B (zh) | 眼部装置 | |
| JP6275137B2 (ja) | 治療薬分与デバイスおよびその作製方法 | |
| US20060210604A1 (en) | Ocular delivery of polymeric delivery formulations | |
| Amrutkar et al. | Nanocarriers for ocular drug delivery: recent advances and future opportunities | |
| Calles et al. | Polymers in ophthalmology | |
| Karthikeyan et al. | The concept of ocular inserts as drug delivery systems: An overview. | |
| US11565023B2 (en) | Method of corneal transplantation or corneal inlay implantation with cross-linking | |
| Rupenthal | Drug-device combination approaches for delivery to the eye | |
| Lee et al. | Advances in ophthalmic drug delivery technology for postoperative management after cataract surgery | |
| Kim et al. | Nanostructured materials for ocular delivery: nanodesign for enhanced bioadhesion, transepithelial permeability and sustained delivery | |
| Kaushik et al. | Novel approaches in ocular drug delivery-A revolution | |
| Nayak et al. | Recent advances in ocular drug delivery systems | |
| Rupenthal et al. | Progress in ocular drug delivery: challenges and constraints | |
| Tekko et al. | Microneedles for ocular drug delivery and targeting: challenges and opportunities |